Novartis drug Afinitor® met primary endpoint of Phase III study in women with advanced breast cancer

London 2012 partner, GlaxoSmithKline, shares scientific expertise with WADA to help fight against abuse of drugs in sport
GlaxoSmithKline signed a long-term agreement with the World Anti-Doping Agency...

Pfizer affirms CHANTIX/CHAMPIX as important treatment option for smokers wanting to quit
An effective and appropriate treatment option for adult smokers wanting to quit...

Biogen Idec researchers identify novel approach for promoting Remyelination
Results from a study that suggest that inhibiting death receptor-6 (DR6) function may represent a novel approach...

Lilly quality leader Walsh appointed to company’s executive committee
Fionnuala Walsh, Ph.D., will join the executive committee of Eli Lilly and Company on July 1...

Lundbeck appoints Senior Vice President of HR
H. Lundbeck A/S has appointed Teddy Hebo Larsen as Senior Vice President of HR...

Novartis receives FDA approval for Arcapta(TM) Neohaler(TM)
Novartis announced that the US FDA approved once-daily Arcapta(TM) Neohaler(TM) (indacaterol inhalation powder)...

Merck statement on voluntary submission of clinical research protocols
For its investigational and approved products...

GlaxoSmithKline receives new approval for Rotarix and significant new indication for Lamictal® (lamotrigine) in Japan
GSK announced that its rotavirus vaccine has received approval in Japan...

AstraZeneca’s NEXIUM receives first regulatory approval in Japan for the treatment of acid-related diseases
NEXIUM 10 mg and 20 mg capsules have received regulatory approval in Japan...

Merck receives approval to market GARDASIL®, ZOLINZA® and CUBICIN®
Merck announced that the Japanese MHLW approved three products – GARDASIL®, ZOLINZA® and CUBICIN®...

Novartis receives approval in Japan for Onbrez® Inhalation Capsules
Novartis has received regulatory approval in Japan for Onbrez® Inhalation Capsules (indacaterol)...

Pfizer announces data presentations for investigational compounds in its lung cancer portfolio
Pfizer Inc. will present early and mid-stage data from its lung cancer portfolio...